Completed PHASE3 INTERVENTIONAL 1-arm NCT02346721

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection

Sponsor: Gilead Sciences

Interventions SOF/VEL

Updated 9 times since 2017 Last updated: Oct 19, 2018 Started: Feb 23, 2015 Primary completion: Mar 23, 2016 Completion: Jun 15, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hepatitis C Virus Infection, this trial is completed. The trial is conducted by Gilead Sciences and has accumulated 9 data snapshots since 2015. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Dec 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2018 — Dec 2018 [monthly]

Completed PHASE3
Jun 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Jun 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gilead Sciences

Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Antwerp, Belgium , Atlanta, United States , Aurora, United States , Baltimore, United States , Berlin, Germany , Boston, United States , Brussels, Belgium , Clermont-Ferrand, France , Clichy, France , Cologne, Germany and 44 more locations